{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:12:57Z","timestamp":1791972777411,"version":"4.3.4"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ejca.2022.03.029","type":"journal-article","created":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T22:59:46Z","timestamp":1651445986000},"page":"74-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Avelumab in unresectable\/metastatic, progressive, grade 2\u20133 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials"],"prefix":"10.1016","volume":"169","author":[{"given":"D.L.","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Rodriguez-Freixinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Wasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Iscoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Raskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Myrehaug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Thawer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejca.2022.03.029_bib1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/cncr.29099","article-title":"Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes","volume":"121","author":"Hallet","year":"2015","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2022.03.029_bib2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1530\/ERC-15-0075","article-title":"Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma","volume":"22","author":"Hadoux","year":"2015","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2022.03.029_bib3","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1530\/ERC-12-0002","article-title":"FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3","volume":"19","author":"Hentic","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2022.03.029_bib4","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3390\/cancers12010206","article-title":"Outcomes of capecitabine and temozolomide (CAPTEM) in advanced neuroendocrine neoplasms (NENs)","volume":"12","author":"Thomas","year":"2020","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.ejca.2022.03.029_bib5","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s00259-017-3821-2","article-title":"Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis","volume":"45","author":"Thang","year":"2018","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"16","key":"10.1016\/j.ejca.2022.03.029_bib6","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejca.2022.03.029_bib7","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"10183","key":"10.1016\/j.ejca.2022.03.029_bib8","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ejca.2022.03.029_bib9","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1158\/1078-0432.CCR-19-3014","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced neuroendocrine tumors: results from the phase II KEYNOTE-158 study","volume":"26","author":"Strosberg","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ejca.2022.03.029_bib10","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/s41416-020-0775-0","article-title":"Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials","volume":"122","author":"Vijayvergia","year":"2020","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2022.03.029_bib11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1530\/ERC-20-0382","article-title":"Spartalizumab in metastatic, well\/poorly-differentiated neuroendocrine neoplasms","volume":"28","author":"Yao","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2022.03.029_bib12","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000488996","article-title":"Immune checkpoint inhibitors in the treatment of patients with neuroendocrine neoplasia","volume":"41","author":"Weber","year":"2018","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.ejca.2022.03.029_bib13","series-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","author":"Kaufman","year":"2016"},{"issue":"26","key":"10.1016\/j.ejca.2022.03.029_bib14","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma","volume":"374","author":"Nghiem","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.03.029_bib15","series-title":"Organisation mondiale de la sant\u00e9, Centre international de recherche sur le cancer. WHO classification of tumours","author":"Lokuhetty","year":"2019"},{"key":"10.1016\/j.ejca.2022.03.029_bib16","series-title":"WHO classification of tumours of endocrine organs. 4. Auflage","first-page":"355","year":"2017"},{"issue":"9","key":"10.1016\/j.ejca.2022.03.029_bib17","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 world Health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification","volume":"10","author":"Travis","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2022.03.029_bib18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2022.03.029_bib20","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/PAS.0000000000000408","article-title":"The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms","volume":"39","author":"Basturk","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ejca.2022.03.029_bib21","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s12022-014-9313-z","article-title":"The 2010 WHO classification of digestive neuroendocrine neoplasms: a critical appraisal four years after its introduction","volume":"25","author":"Rindi","year":"2014","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.ejca.2022.03.029_bib22","author":"Fottner"},{"issue":"13","key":"10.1016\/j.ejca.2022.03.029_bib23","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1002\/cncr.32883","article-title":"Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: results from the KEYNOTE-028 study","volume":"126","author":"Mehnert","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2022.03.029_bib24","volume":"29","author":"Yao","year":"2018","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2022.03.029_bib25","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1158\/1078-0432.CCR-19-4000","article-title":"Efficacy, safety and biomarkers of toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms: a multiple-center phase Ib trial","volume":"26","author":"Lu","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.03.029_bib26","doi-asserted-by":"crossref","first-page":"S770","DOI":"10.1016\/j.annonc.2020.08.1370","article-title":"1157O A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: the DUNE trial (GETNE 1601)","volume":"31","author":"Capdevila","year":"2020","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2022.03.029_bib27","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-19-3356","article-title":"A phase II basket trial of dual anti\u2013CTLA-4 and anti\u2013PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors","volume":"26","author":"Patel","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.ejca.2022.03.029_bib28","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.1158\/1078-0432.CCR-20-1804","article-title":"Comprehensive genomic profiling of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs)","volume":"26","author":"Puccini","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ejca.2022.03.029_bib29","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.03.029_bib30","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3389\/fonc.2020.00132","article-title":"Immune checkpoint markers in neuroendocrine carcinoma of the digestive system","volume":"10","author":"Xing","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2022.03.029_bib31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"issue":"20","key":"10.1016\/j.ejca.2022.03.029_bib32","doi-asserted-by":"crossref","first-page":"29794","DOI":"10.18632\/oncotarget.7631","article-title":"The effect of chemotherapy on programmed cell death 1\/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response","volume":"7","author":"Luo","year":"2016","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.ejca.2022.03.029_bib33","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ejca.2022.03.029_bib34","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.ejca.2022.03.029_bib35","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.ejca.2022.03.029_bib36","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ejca.2022.03.029_bib37","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922001757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922001757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:35:29Z","timestamp":1760733329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922001757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":36,"alternative-id":["S0959804922001757"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.03.029","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Avelumab in unresectable\/metastatic, progressive, grade 2\u20133 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.03.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}